Pharming Q3 Revenue Up 21% to $117.6M; Guidance Tightened, Operating Profit Jumps 89%
PHAR sits 31% above its 52-week low of $9.11.
Summary
Pharming delivered Q3 revenue of $117.6 million, up 21% year-over-year and above expectations, with RUCONEST recovering to $93.8 million (+14%) on stabilized U.S. demand and seasonal channel inventory, and Joenja at $23.8 million (+58%) on U.S. uptake plus Germany and Japan launches. Operating profit jumped 89% to $29.9 million and net profit was $22.4 million versus $7.5 million a year ago. The company tightened 2026 revenue guidance to $380-390 million from $375-395 million, narrowing the range around the midpoint. Cash flow from operations was $32.4 million in the quarter, lifting cash and securities to $190.9 million. The key forward item is Phase II topline data for leniolisib in CVID expected in November 2026 — a population far larger than APDS and the basis for a potential registrational Phase III. This follows the October 22 pre-announcement of the revenue figure; the profit, guidance and cash detail are new.
At the time of this announcement, PHAR was trading at $11.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $833.6M. The 52-week trading range was $9.11 to $21.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.